Esperance Pharmaceuticals has started Phase 1 clinical studies of a drug designed to seek and destroy cancer cells. The Baton Rouge-based biotech firm is testing EP-100 in patients with advanced solid…
Already an INSIDER? Sign in.
We are glad you enjoy reading Business Report.
Continue reading this story and get ACCESS to all our content from any device with a subscription now.
- Get access to more than a decade of story archives.
- Get access to our searchable data center of TOP LISTS.
- Get exclusive content only available to INSIDERS.